跳至主要内容
临床试验/EUCTR2014-004915-35-DE
EUCTR2014-004915-35-DE进行中(未招募)1 期

A randomized, double blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of inhaled QBW276 in patients with cystic fibrosis - Safety,pharmacokinetics and pharmacodynamics study of inhaledQBW276 in patients with cystic fibrosis

ovartis Pharma AG0 个研究点目标入组 16 人开始时间: 2015年10月14日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - Cohorts 1 and 2 = any genotype on any standard of care treatment
  • - Cohort 3 = F508del homozygotes on standard of care at that time
  • - FEV1 between 40 and 100%
  • - LCI2.5 = 8 if FEV1 is more than 80%
  • Other protocol-defined inclusion/exclusion criteria may apply.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 56
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Adrenal or electrolyte abnormalities
  • - Lung transplant
  • - Autonomic dysfunction (e.g. recurrent episodes of fainting, palpitations, etc.)
  • Other protocol-defined inclusion/exclusion criteria may apply

研究者

相似试验

Safety and effect of QBW276 in patients with cystic... | 临床试验